Obinutuzumab - Roche
At a glance
- Drug Originator GLYCART Biotechnology
- Drug Licenced by Chugai Pharmaceutical; Nippon Shinyaku
- Drug Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies; Urologics
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death inhibitors; Cell death stimulants
- USA Patent Applicants GENENTECH
- USA Patents 80
- BLAs 1
- International Patents 1,163

Disclaimer